
Tevogen Bio
@tevogenbio
Specialty immunotherapy biotech developing off-the-shelf precision #Tcell therapeutics in #oncology, #neurology, and #virology. $TVGN
ID: 1371813486544687110
http://www.tevogen.com 16-03-2021 13:20:29
417 Tweet
587 Followers
220 Following

๐ฐ ๐๐ซ๐๐ฌ๐ฌ ๐๐๐ฅ๐๐๐ฌ๐: globenewswire.com/news-release/2โฆ ๐๐จ๐ง๐ญ๐ซ๐ข๐๐ฎ๐ญ๐ข๐จ๐ง ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ ๐ฅ๐๐๐๐๐ซ๐ฌ๐ก๐ข๐ฉโ๐ฌ ๐ฎ๐ง๐๐๐ซ๐ฌ๐ญ๐๐ง๐๐ข๐ง๐ ๐จ๐ ๐ญ๐ก๐ ๐ข๐ฆ๐ฉ๐จ๐ซ๐ญ๐๐ง๐๐ ๐๐ ๐ฐ๐ข๐ฅ๐ฅ ๐ฉ๐ฅ๐๐ฒ ๐ข๐ง ๐๐ซ๐ฎ๐ ๐๐ข๐ฌ๐๐จ๐ฏ๐๐ซ๐ฒ โThis personal investment by our CEO



โณ ๐๐๐ฏ๐จ๐ ๐๐ง ๐๐ข๐ฆ๐ ๐๐๐ฉ๐ฌ๐ฎ๐ฅ๐ โณ Tevogen Bio's positive proof-of-concept clinical trial. Learn more about the results at: ashpublications.org/bloodadvances/โฆ $TVGN #affordable #accessible #celltherapy #clinicaltrials Blood Advances


๐๐ฐ๐จ ๐๐ง๐๐ซ๐ ๐ข๐ณ๐ข๐ง๐ ๐๐๐ฒ๐ฌ ๐๐ญ ๐ญ๐ก๐ CMSGov 2025 ๐๐ฎ๐๐ฅ๐ข๐ญ๐ฒ ๐๐จ๐ง๐๐๐ซ๐๐ง๐๐ #๐๐๐๐๐ฎ๐๐ฅ๐๐จ๐ง2025. Reflecting on the event, Tevogenโs Head of Government Affairs and Patient Access, David Banko, commented โDrOzCMS โMake America Healthy Againโ fireside



โณ ๐๐๐ฏ๐จ๐ ๐๐ง ๐๐ข๐ฆ๐ ๐๐๐ฉ๐ฌ๐ฎ๐ฅ๐ โณ Mittul Mehta CIO and Head of Tevogen.AI in conversation with Brad Mehl of Future Sights and Medium about AI Innovation in Drug Discovery. ๐medium.com/future-sights/โฆ "One of the most interesting use cases that we deal



Dr. Ryan Saadi, Tevogen Bio founder and CEO, gifts $500,000 for the build-out and first-year operating costs of the company's expanded corporate HQ in Warren. njbiz.com/tevogen-warrenโฆ


๐ฐ ๐๐ซ๐๐ฌ๐ฌ ๐๐๐ฅ๐๐๐ฌ๐: globenewswire.com/news-release/2โฆ $TVGN #affordable #accessible #celltherapy #AI #ArtificialIntelligence Microsoft Databricks ยท Tevogen.AIโs model drastically reduces target analysis and has the potential to generate billions in cost savings


#๐๐๐๐๐ ๐ฐ ๐๐ซ๐๐ฌ๐ฌ ๐๐๐ฅ๐๐๐ฌ๐: globenewswire.com/news-release/2โฆ โThrough the development and utilization of the PredicTcell platform we have uncovered new insights and are able to quickly analyze significantly larger datasets, potentiallyย resulting in better accuracy and


๐ฐ ๐๐ซ๐๐ฌ๐ฌ ๐๐๐ฅ๐๐๐ฌ๐: globenewswire.com/news-release/2โฆ โช Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapies โช Initiative to support Tevogen Bioโs ExacTcellโข pipeline with a goal of enhancing commercial viability and


๐ฐ ๐๐ซ๐๐ฌ๐ฌ ๐๐๐ฅ๐๐๐ฌ๐: globenewswire.com/news-release/2โฆ โOur continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,โ said Dr. Ryan Saadi, Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq). โThis facility has potential to efficiently scale our



#๐๐๐๐๐ ๐ฐ ๐๐ซ๐๐ฌ๐ฌ ๐๐๐ฅ๐๐๐ฌ๐: globenewswire.com/news-release/2โฆ โIโm pleased with Tevogen.AIโs continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,โ said Dr. Ryan Saadi, Founder and Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq).


